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Dear Sir,
There is a growing body of literature concerning the
intranasal endoscopic approach to orbital diseases. We
agree on the reasons behind the choice to approach the
medial orbit endonasally insofar as we have recently pub-
lished a method to manage medial wall fractures [1].
It appears that one of the most frequent reasons to
approach the orbit transnasally is to remove a ‘‘cavernous
hemangioma’’ (CH) and recent papers describe CH as a
tumor.
Hooper in 1828 clarified that the suffix ‘‘-oma’’ should
be used for tumors only [2].
A landmark paper from Mulliken and Glowacki [3]
demonstrated that vascular anomalies are divided in tumors
and malformations based on their histological features:
tumors have cells that possess an intrinsic anomalous
turnover rate while malformations do not. The most fre-
quent among vascular tumors is Infantile Hemangioma
which is the most common tumor of infancy and inherently
tends to regress at around 3–5 years.
ISSVA, the International Society for the Study of Vas-
cular Anomalies has proposed a classification that has been
unanimously accepted [4]. This divides Tumors (benign,
borderline, and malignant) from Malformations (Simple:
Capillary, Lymphatic, Venous, Arteriovenous Malforma-
tions, Arteriovenous Fistula; Combined; Of Major Named
Vessels; Associated with other Anomalies).
Thus, the suffix -oma should never be used to describe
vascular malformations.
Nevertheless, many Authors still refer to ‘‘cavernous
hemangioma’’.
To be correct, the term should indicate a tumor. Are
cavernous hemangioma tumors? No. In a recent research
Rootman et al. [5] have demonstrated that CHs are non-
infiltrating, focal venous malformations. They lack hyper-
plasia, that is, the cell turnover rate is not altered and they
grow (when they do it, by an average 10 % per year) owing
to phenomena of localized intravascular coagulation (LIC)
and subsequent inflammation [6]. Just like other Puig Type
I venous malformations, they are (almost) excluded from
the general circulation [7].
Is this just academia? Again, no. Since isolated venous
malformations of the orbit are not tumors, indications for
surgery and, especially, the related informed consent must
take this into consideration. Only those malformations
presenting clear symptoms, like reduction in visual acuity
and/or diplopia should be managed surgically. Another,
less agreed on, indication is morphologically significant
exophthalmos. Small, asymptomatic malformations, espe-
cially those located intraconally, can be just observed over
time. Nonsurgical measures such as low molecular weight
heparin could be used to stem episodes of LIC [6].
Thus we believe that the term ‘‘cavernous hemangioma’’
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